- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02328963
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (EVERCMV)
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
Study Overview
Status
Intervention / Treatment
Detailed Description
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after kidney transplantation. Therefore most of the patients receive an universal prophylaxis. On the contrary to CMV naïve patients, seropositive recipients (R+) have already mounted a specific immunologic response directed against the virus, which is not completely abrogated by immunosuppressive drugs. Although CMV infection management guidelines offer little guidance on immunosuppressive therapy for preventing CMV infection and disease, recent data plead for reappraising the place of mTOR inhibitors in this situation. The potential anti-CMV action of these molecules could be added to their potential antitumor effect and their equivalent immunosuppressive efficacy in kidney transplant recipients at low immunological risk. By the way, it could represent an alternative of a systematic universal prophylaxis in R+ kidney transplant recipients. However, the proof of this anti-CMV action must be confirmed in vivo in a study, which could have a close monitoring of CMV infection.
We therefore designed a prospective multicentric randomized controlled trial comparing an immunosuppressive regimen based on everolimus and reduced dose of cyclosporine A to a regimen based on mycophenolic acid and standard dose of cyclosporine A, in order to demonstrate the superiority of the first one in the prevention of CMV infection.
Subjects will be randomized to one of the two treatment arms and will be followed for a period of 12 months. Whole blood CMV real time PCR will be performed every week during the first three months, then every two weeks from Month 3 to Month 6, then at Months 8, 10 and 12. Incidence of CMV infection will be compared between the two arms at 6 and 12 months post-transplantation.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- CHU de Bordeaux
-
Brest, France, 29609
- CHU La Cavale Blanche
-
Caen, France, 14033
- CHRU Caen - Hôpital de Caen
-
Limoges, France
- CHU de Limoges - Hôpital Dupuytren
-
Lyon, France, 69003
- Hopital Edouard Herriot
-
Paris, France, 75015
- APHP - Hopital Necker
-
Paris, France, 94275
- APHP - Kremlin Bicêtre
-
Strasbourg, France
- CHRU Strasbourg
-
Toulouse, France, 31000
- CHU de Toulouse - Hôpital Rangueil
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years.
- End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation.
- Patient seropositive for CMV (confirmed within two weeks post-transplant) and having received an allograft from a CMV seropositive or seronegative donor.
- Receiving a kidney transplant from a deceased or living donor with compatible ABO blood type.
- Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study and two months later the discontinuation of the test drug.
- Total ischemia time below 36 hours.
- Capable of understanding the purpose and risks of the study.
- Fully informed and having given written informed consent (signed Informed Consent has been obtained).
- Affiliation to the social security regimen
Exclusion Criteria:
- CMV seronegative patient.
- Historical or current TGI (French equivalence of calculated PRA) > 85 %
- Presence of historical or current anti-HLA donor specific antibodies
- Patient who received anti-CMV therapy within the past 30 days prior to screening.
- Receiving or having previously received an organ transplant other than a kidney.
- Receiving a graft from a non-heart-beating donor.
- Patient known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV; HBs Ag positive) or Hepatitis C (HCV; anti-HCV Ab positive).elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels ≥ 2 times the upper value of the normal range of the investigational site or receiving a graft from a hepatitis C or B positive donor.
- Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.
- Known allergy or intolerance to everolimus, valganciclovir, ganciclovir, mycophenolic acid, basiliximab, corticosteroids, or cyclosporine A or any of the product excipients.
- Severe hyperlipidemia defined by: total cholestérol ≥ 9,1 mmol/L (≥ 350 mg/dL) et/ou triglycérides ≥ 8,5 mmol/l (≥ 750 mg/dL) in spite an adequate medication.
Patient has adequate hematological post-transplant defined as:
- Absolute neutrophil count (ANC) > 1000 cells/μL.
- Platelet count > 50,000 cells/μL.
- Hemoglobin > 8.0 g/dL.
- Requiring initial therapy with induction immunosuppressive antibody preparations, such as anti-thymocyte globulins or rituximab or IVIG.
- Currently participating in another clinical trial investigating drugs. Observational studies are not considered as an exclusion criteria
- Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.
- Unlikely to comply with the visits scheduled in the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Everolimus
Everolimus + reduced dose of cyclosporine A
|
Everolimus : 0.75 bid, targeted to 3-8 ng/ml Cyclosporin A : CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12. Corticosteroids : Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study Basiliximab :Day 0: 20 mg ; Day 4: 20 mg |
Active Comparator: mycophenolic acid
mycophenolic acid + standard dose of cyclosporin A
|
Mycophenolic acid : 1080 mg bid for one month, then 720 mg bid Cyclosporin A : CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12. Corticosteroids : Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study Basiliximab :Day 0: 20 mg ; Day 4: 20 mg |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants without CMV infection and without graft loss in CMV seropositive kidney transplant recipients.
Time Frame: 6 months post-transplantation
|
The primary objective of this study is to compare the survival without CMV infection and without graft loss in CMV seropositive kidney transplant recipients, within the first 6 months post-transplantation when treated with an immunosuppressive regimen including everolimus (Certican®) and reduced dose (RD) of cyclosporine A (Néoral®) versus an immunosuppressive regimen with mycophenolic acid (Myfortic®) and standard dose (SD) of cyclosporine A (Néoral®).
|
6 months post-transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who will develop CMV disease
Time Frame: 6 and 12 months post-transplantation
|
The proportion of patients who will develop CMV disease during the first 6 and 12 months post-transplantation (CMV disease includes both CMV syndrome and CMV tissue-invasive disease).
|
6 and 12 months post-transplantation
|
Proportion of patient with graft loss, death and loss of follow-up
Time Frame: 12 months post-transplantation
|
12 months post-transplantation
|
|
Proportion of patient with acute rejection, graft loss, death and loss of follow-u
Time Frame: 12 months
|
12 months
|
|
Level to the first CMV DNAemia
Time Frame: Throughout the study
|
Throughout the study
|
|
Time to the first CMV disease
Time Frame: Throughout the study
|
Throughout the study
|
|
Proportion of patients treated for CMV infection in both groups
Time Frame: 6 months
|
6 months
|
|
Half-life of decreasing of DNAemia
Time Frame: after initiation of anti-CMV therapy
|
after initiation of anti-CMV therapy
|
|
Occurrence of treatment failure, defined as the absence of viral eradication.
Time Frame: Day 49 (or 8 weeks) after the initiation of anti-CMV therapy
|
Day 49 (or 8 weeks) after the initiation of anti-CMV therapy
|
|
Occurrence of CMV mutation (UL97 ou UL54) associated with a resistance to an anti-CMV therapy.
Time Frame: Throughout the study
|
Throughout the study
|
|
Graft function
Time Frame: 6 and 12 months post-transplantation
|
Graft function defined as glomerular filtration rate (GFR) estimated by simplified MDRD formula and proteinuria/creatininuria ratio.
|
6 and 12 months post-transplantation
|
Proportion of patients with biopsy-proven acute rejection (BPAR)
Time Frame: 6 and 12 months post-transplantation
|
6 and 12 months post-transplantation
|
|
Degree of interstitial fibrosis/tubular atrophy
Time Frame: 12 months on protocol biopsies
|
12 months on protocol biopsies
|
|
Graft and patient survival
Time Frame: 6 and 12 months post-transplantation
|
6 and 12 months post-transplantation
|
|
Proportion of BK virus viremia
Time Frame: month 1, 3, 6 and 12
|
month 1, 3, 6 and 12
|
|
Proportion of patients with adverse events (AE) and/or serious adverse events (SAE) including opportunistic infections and neoplasias.
Time Frame: 12 months
|
12 months
|
|
Proportion of patients with haematological disorders
Time Frame: 12 months
|
The proportion of patients with haematological disorders (neutropenia, anaemia, thrombopenia)
|
12 months
|
Proportion of patients with diarrhea
Time Frame: 12 months
|
12 months
|
|
Proportion of dyslipidemia
Time Frame: 12 months
|
12 months
|
|
Proportion of patients with occurrence of New Onset Diabetes Mellitus as defined by American Diabetic Association (ADA) criteria.
Time Frame: 12 months
|
12 months
|
|
Proportion of patients who will discontinue the immunosuppressive treatment and the reasons why.
Time Frame: 12 months
|
12 months
|
|
Proportion of patients with delayed graft function
Time Frame: 12 months
|
12 months
|
|
Proportion of lymphocele
Time Frame: 12 months
|
12 months
|
|
Time to the first CMV DNAemia
Time Frame: Throughout the study
|
Throughout the study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lionel COUZI, MD, University Hospital, Bordeaux
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Disease Attributes
- DNA Virus Infections
- Herpesviridae Infections
- Infections
- Communicable Diseases
- Cytomegalovirus Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Mycophenolic Acid
- Everolimus
Other Study ID Numbers
- CHUBX2012/29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transplantation Infection
-
Ain Shams UniversityActive, not recruitingTransplantation Infection | Liver Grafting | Hepatic TransplantationEgypt
-
Universitaire Ziekenhuizen KU LeuvenCompletedTransplantation InfectionBelgium
-
Novartis PharmaceuticalsCompleted
-
Asan Medical CenterKorea Advanced Institute of Science and TechnologyTerminatedKidney TransplantationKorea, Republic of
-
NovartisCompleted
-
University Hospital, GrenobleNot yet recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Cytomegalovirus Infections | Lung TransplantationFrance
-
University of Colorado, DenverAgency for Healthcare Research and Quality (AHRQ)RecruitingTransplantation Infection | VaccinationUnited States
-
University Hospital, Strasbourg, FranceRecruiting
-
University of PittsburghCenters for Disease Control and PreventionCompleted
-
University of British ColumbiaVancouver Coastal Health Research InstituteCompletedTransplantation InfectionCanada
Clinical Trials on Everolimus
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
The Netherlands Cancer InstituteActive, not recruitingNeuroendocrine CarcinomasNetherlands
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
University of LuebeckTerminatedCoronary Artery DiseaseGermany
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Leiden University Medical CenterUnknownHead and Neck CancerNetherlands
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of
-
Centre Leon BerardSuspended